title: Pharmacologic resistance in colorectal cancer: a review.
abstract: Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.
authors.affiliation: Division of Hematology/ Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: William A
authors.initials: WA
authors.lastname: Hammond
authors.affiliation: Division of Hematology/ Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Abhisek
authors.initials: A
authors.lastname: Swaika
authors.affiliation: Division of Hematology/ Oncology, Mayo Clinic Cancer Center, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA.
authors.forename: Kabir
authors.initials: K
authors.lastname: Mody
keywords: colon adenocarcinoma; colon cancer; resistance